Center for Cell and Gene Therapy

15th Annual SCOPE: Summit for Clinical Ops Executives Puts Spotlight on the Cell & Gene Therapies Supply Chain & Medical Device Trials, February 11-14, 2024, Orlando, FL

Retrieved on:

Thursday, November 2, 2023

NEEDHAM, Mass., Nov. 2, 2023 /PRNewswire-PRWeb/ -- In response to the rapid expansion of the cell and gene therapy (CGT) market valued at $7.28 billion in 2022 and a predicted compound annual growth rate (CAGR) of 26.6% from 2023 to 2030 (as reported by MarketsandMarkets™), Cambridge Healthtech Institute (CHI) delves into the diverse clinical supply chain infrastructure designed for today's approved Cell and Gene Therapies (CGT), as well as supply strategies for those presently engaged in clinical trials, at its 15th annual SCOPE: Summit for Clinical Ops Executives, taking place February 11-14, 2024, in Orlando, FL, and online.

Key Points:

The SCOPE Summit brings together over 3,300 executives and clinical operations experts.
All understand the necessity of making improvements to the clinical supply chain which is essential to meet the growing complexity of clinical trials, particularly in the context of rapidly evolving cell and gene therapies that are reshaping treatments and challenging established supply chain paradigms.
The summit will feature a dedicated stream on Clinical Supply, encompassing 2 distinct conferences: "Data Technology for End-to-End Clinical Supply Management" and "Clinical Supply Chain Strategies to Align Process, Products and Patients."
( https://www.scopesummit.com/Clinical-Supply-Management )
Furthermore, the event brings back its Medical Device Trials conferences focusing on trial design, operations, regulations, quality, and data management.

Agilisium Recognized as a 'Product Challenger' in 2023 ISG Provider Lens™ for AWS Data Analytics and Machine Learning

Retrieved on:

Wednesday, November 1, 2023

Ecosystem, State Migration Service (Azerbaijan), Center for Cell and Gene Therapy, Synthetic media, ISG, Machine learning, Generative, Contender, Cell, Gene, Drug discovery, AWS, Digital, Investment, Medical device

LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- Agilisium Consulting, a leading provider of Advanced Data Analytics and Generative AI solutions, today announced that it has been recognized as a "Product Challenger" in the 'AWS Data Analytics and Machine Learning' and as a "Contender" in 'AWS Migration Services' quadrant in the ISG Provider Lens™ AWS Ecosystem Partners 2023 US Quadrant Report.

Key Points:

LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- Agilisium Consulting, a leading provider of Advanced Data Analytics and Generative AI solutions, today announced that it has been recognized as a "Product Challenger" in the 'AWS Data Analytics and Machine Learning' and as a "Contender" in 'AWS Migration Services' quadrant in the ISG Provider Lens™ AWS Ecosystem Partners 2023 US Quadrant Report.
Agilisium makes investments in building Advanced Analytics capabilities and Generative AI Solutions with AWS services.
These solutions make Agilisium as unique AWS Data Analytics and Machine Learning solutions company.
Click here , to access the ISG Provider Lens™ AWS Ecosystem Partners 2023 U.S. Quadrant Report

Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan

Retrieved on:

Tuesday, October 24, 2023

Center for Cell and Gene Therapy, Investment, Accreditation, Research, SGPI, CGT, Cell, Gene, Patient, Miniaturization, Pharmaceutical industry

I would like to express my gratitude to the French government for its continued support and to the SGPI and BPI France, through which this grant has been awarded.

Key Points:

I would like to express my gratitude to the French government for its continued support and to the SGPI and BPI France, through which this grant has been awarded.
Astraveus' SKALE project perfectly aligns with France 2030 objectives to establish the nation as a leader in healthcare innovation, particularly in bioprocessing.
It also matches BPI France's mandate to deliver the ambition of the French government to strongly support the promote French industry."
Bruno Bonnell, General Secretary for Investment, responsible for France 2030 program, commented: "This funding is awarded to French companies that are world leaders in developing the innovations that will shape the world of tomorrow.

Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan

Retrieved on:

Tuesday, October 24, 2023

Center for Cell and Gene Therapy, Investment, Accreditation, Research, SGPI, CGT, Cell, Gene, Patient, Miniaturization, Pharmaceutical industry

I would like to express my gratitude to the French government for its continued support and to the SGPI and BPI France, through which this grant has been awarded.

Key Points:

I would like to express my gratitude to the French government for its continued support and to the SGPI and BPI France, through which this grant has been awarded.
Astraveus' SKALE project perfectly aligns with France 2030 objectives to establish the nation as a leader in healthcare innovation, particularly in bioprocessing.
It also matches BPI France's mandate to deliver the ambition of the French government to strongly support the promote French industry."
Bruno Bonnell, General Secretary for Investment, responsible for France 2030 program, commented: "This funding is awarded to French companies that are world leaders in developing the innovations that will shape the world of tomorrow.

NecstGen and ProteoNic report development of improved viral vectors through the application of premium 2G UNic™ technology

Retrieved on:

Tuesday, September 19, 2023

Tissue, LV, Center for Cell and Gene Therapy, Gene, Leiden Bio Science Park, Proteon Therapeutics, AAV, CDMO, Patient, Cell, Vaccine

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.

Key Points:

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.
Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production processes.
We will continue our efforts aimed at improving AAV and LV vectors, catering to both transient production systems and stable viral producer cell lines".
ProteoNic will offer licensing and co-development opportunities, while NecstGen plans to apply the technology in its CDMO business.

NecstGen and ProteoNic report development of improved viral vectors through the application of premium 2G UNic™ technology

Retrieved on:

Tuesday, September 19, 2023

Tissue, LV, Center for Cell and Gene Therapy, Gene, Leiden Bio Science Park, Proteon Therapeutics, AAV, CDMO, Patient, Cell, Vaccine

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.

Key Points:

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.
Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production processes.
We will continue our efforts aimed at improving AAV and LV vectors, catering to both transient production systems and stable viral producer cell lines".
ProteoNic will offer licensing and co-development opportunities, while NecstGen plans to apply the technology in its CDMO business.

ATLATL Beijing International Innovation Center Becomes Fully Operational

Retrieved on:

Tuesday, September 5, 2023

Phase II of the ATLATL Beijing International Innovation Center (referred to as "Beijing ATLATL"), located in the Zhongguancun Life Science Park, has officially commenced operations, marking the comprehensive launch of Beijing ATLATL.

Key Points:

Phase II of the ATLATL Beijing International Innovation Center (referred to as "Beijing ATLATL"), located in the Zhongguancun Life Science Park, has officially commenced operations, marking the comprehensive launch of Beijing ATLATL.
Beijing ATLATL, initiated in 2021, has served more than 20 innovation teams, with total funding raised of more than 2 billion RMB.
Dr. PC Zhu, founder and CEO of ATLATL Innovation Center, stated that after more than two years in Beijing, ATLATL, leveraging its core R&D strength, has been vigorously constructing the Beijing ATLATL International Innovation Platform, pooling innovation and sourcing innovation.
Through sourcing and pooling innovation, ATLATL quickly connects China's biopharmaceutical innovation "seeds" with international resources, accelerates the development of "Life Valley" in Beijing, creates a globally leading innovation platform, and builds a world-class biopharmaceutical innovation cluster.

Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

Retrieved on:

Friday, September 1, 2023

NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023.

Key Points:

NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023.
Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer.
"I am pleased to join the Board of Karyopharm at this exciting time in the company's next phase of growth," said Dr. Su.
"We are thrilled to welcome such a strong strategic advisor and industry leader to our Board of Directors."

AGC Biologics Completes Expansion at Milan Cell and Gene Therapy Development and Manufacturing Site

Retrieved on:

Wednesday, August 9, 2023

Biotechnology, Pharmaceutical, Health, Messenger RNA, GMP, DNA, Plasmid, Gene, Center for Cell and Gene Therapy, Viral vector, Gene-centered view of evolution, AGC, Messenger, CDMO, CGMP, Cell, Heidelberg, Vaccine

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.

Key Points:

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.
“This is another important milestone for our site and for the AGC Biologics global Cell and Gene network as we prepare to serve more developers,” said Luca Alberici, General Manager, AGC Biologics Milan.
AGC Biologics operates two cell and gene facilities within its global network, one in Milan and one in Longmont, Col, USA.
At each site AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing, and quality/regulatory services, using the latest technology platforms and scientific methods.

Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023

Retrieved on:

Wednesday, July 26, 2023

Marker, Pediatrics, Gene, Center for Cell and Gene Therapy, Baylor University, Houston Methodist Hospital, Department of Medicine – University of Pamplona, EDT, Gene therapy, Cell, Baylor College of Medicine, DSC, Knowledge, Therapy, Bone marrow, Vaccine, Medicine

The virtual event is scheduled to take place on August 9, 2023, at 11:00 a.m. EDT.

Key Points:

The virtual event is scheduled to take place on August 9, 2023, at 11:00 a.m. EDT.
During the one hour virtual event, featured panelists will provide an overview and discuss the limitations of CAR-T cell therapies.
Panelists will also highlight the potential impact and unique merits of the multiple tumor-associated antigen (multiTAA) targeted therapy Marker is developing in comparison to single antigen targeted therapies.
Juan F. Vera, M.D., President and Chief Executive Officer, Marker Therapeutics
The extensive knowledge and unique perspectives of the panelists promises a profound and impactful discussion.